Reset filter
Keywords
Insuffisance coronarienne ×
Mostra di più Keywords
Sommario
  1. 1. Test clinico
  2. 2. Documentazione di routine
  3. 3. Registro / studio di coorte
  4. 4. Garanzia di qualità
  5. 5. Dati Standard
  6. 6. Risultato segnalato dal paziente
  7. 7. Specialità mediche
Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

143 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Persönliches Interview SHIP-Trend-1 Herz-Kreislauf-Erkrankungen

- 13/02/21 - 1 modulo, 1 ItemGroup, 5 elementi, 1 linguaggio
ItemGroup: Herz-Kreislauf-Erkrankungen
Herz-Kreislauf-Erkrankungen form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name TREND.TREND1.INT.KHK.KHK. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

dbGaP phs000944 eMERGE Clinical Center at Partners HealthCare - Eligibility

- 27/11/24 - 6 moduli, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: IG.elig, IG.elig
Principal Investigator: Scott T. Weiss, MD, MS, Partners HealthCare System, Boston, MA, USA MeSH: Hypercholesterolemia,Asthma,Arthritis, Rheumatoid,Attention Deficit Disorder with Hyperactivity,Bipolar Disorder,Coronary Disease,Depression,Heart Failure,Inflammatory Bowel Diseases,Multiple Sclerosis,Schizophrenia,Stroke https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000944 The Partners HealthCare Biobank is a large research data and sample repository working within the framework of Partners Personalized Medicine. It provides researchers access to high quality, consented samples to help foster research, advance understanding of the causes of common diseases, and advance the practice of medicine. The Partners Biobank provides banked samples (plasma, serum and DNA) collected from consented patients. These samples are available for distribution to Partners HealthCare investigators with appropriate approval from the Partners Institutional Review board (IRB). They are linked to clinical data that originates in the Electronic Medical Record (EMR), as well as additional health information collected in a self-reported survey. The Partners Biobank will be genotyping 25,000 subjects with the Illumina Multiethnic Beadchip 1.6 million SNPs with exome and custom content ( 60,000 LoFs). Of the participants genotyped so far, 4929 of 4962 (99.3%) individuals have genotype data that passed the default quality thresholds for the Infinium array (call rate = 0.99). We are submitting the genotype data to dbGaP for 4929 subjects with 12 phenotypes (based on icd9 codes). We will do annual releases until we reach the full 25,000 genotyped subjects.

pht004847.v1.p1

1 ItemGroup 5 elementi

pht005288.v1.p1

1 ItemGroup 6 elementi

pht004844.v1.p1

1 ItemGroup 2 elementi

pht004845.v1.p1

1 ItemGroup 3 elementi

pht004846.v1.p1

1 ItemGroup 18 elementi

dbGaP phs000925 PAGE: IPM BioMe Biobank - Eligibility

- 28/04/24 - 5 moduli, 1 ItemGroup, 1 elemento, 1 linguaggio
ItemGroup: IG.elig
Principal Investigator: Ruth Loos, PhD, The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA MeSH: Cardiovascular Diseases,Obesity,Diabetes Mellitus, Type 2,Glucose,Kidney Failure, Chronic,Cholesterol, HDL,Cholesterol, LDL,Triglycerides,Coronary Disease,Myocardial Infarction,Inflammation,Stroke,Body Height https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000925 The Institute for Personalized Medicine (IPM) Bio*Me* Biobank is a consented, EMR-linked medical care setting biorepository of the Mount Sinai Medical Center (MSMC) drawing from a population of over 70,000 inpatients and 800,000 outpatient visits annually. MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African American), East Harlem (88% Hispanic Latino), and Upper East Side (88% Caucasian/white) with broad health disparities. IPM Bio*Me* Biobank populations include 28% African American, 38% Hispanic Latino predominantly of Caribbean origin, 23% Caucasian/White. IPM BioMe Biobank disease burden is reflective of health disparities with broad public health impact. Biobank operations are fully integrated in clinical care processes, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicated Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites. This study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study (phs000356).

pht005176.v1.p1

1 ItemGroup 4 elementi

pht005178.v1.p1

1 ItemGroup 6 elementi

pht006203.v1.p1

1 ItemGroup 6 elementi

pht005177.v1.p1

1 ItemGroup 5 elementi

dbGaP phs000703 CATHeterization GENetics (CATHGEN) - pht003668.v1.p1

- 10/01/23 - 6 moduli, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: pht003668
Principal Investigator: MeSH: Coronary Disease,Hypertension,Diabetes Mellitus,Heart Failure https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000703 The CATHGEN biorepository consists of biological samples collected on 9334 sequential consenting individuals undergoing cardiac catheterization at Duke University Medical Center between 2001 and 2010 inclusive. The Institutional Review Board informed consent allowed for 50 mL of blood to be collected from fasting patients through the femoral arterial sheath during the catheterization procedure. Three 7.5 mL EDTA tubes for DNA extraction are stored at -80°C. The Duke Database for Cardiovascular Disease (DDCD) provides the bulk of the clinical data used for analysis. Follow-up includes mortality information gleaned from the National Death Index and Social Security Death Index plus follow-up phone calls and written questionnaires regarding MI, stroke, re-hospitalization, coronary re-vascularization procedures, smoking, exercise, and medication use.

pht003670.v1.p1

1 ItemGroup 16 elementi

pht003672.v1.p1

1 ItemGroup 15 elementi

pht003673.v1.p1

1 ItemGroup 4 elementi

pht003669.v1.p1

1 ItemGroup 5 elementi

pht003671.v1.p1

1 ItemGroup 4 elementi

dbGaP phs000737 NIDDK Genetics of Metabolic Syndrome in an Island Population - Eligibility

- 28/12/22 - 6 moduli, 1 ItemGroup, 1 elemento, 1 linguaggio
ItemGroup: IG.elig
Principal Investigator: Ranjan Deka, PhD, University of Cincinnati, Cincinnati, OH, USA MeSH: Metabolic Syndrome X,Diabetes mellitus type 2,Hypertension, Essential,Dyslipidemia,Coronary Heart Disease,Gout https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000737 The major objective of this study was to conduct a systematic genetic study of metabolic traits involved in metabolic syndrome through collection and analysis of epidemiological, demographic, environmental, and relevant biological and clinical data from a relatively isolated island population of the eastern Adriatic coast of Croatia. The population was chosen for the following reasons: 1) in spite of practicing a largely traditional life style and dietary habits, high rates of obesity, arterial hypertension, dyslipidemia and related metabolic abnormalities were found in previous studies; 2) the population was established by a relatively small number of founders, predominantly of Slavic descent from the mainland during 15th to 18th century AD, a genetically homogeneous population living in a homogeneous environment; 3) sharing a common European ancestry, a relevant population for study in the context of the general US population; 4) Croatian collaborators have been conducting anthropological and genetic studies in these communities for over three decades. There were two major aims of the study: 1) to recruit ~1200 adult participants and collect blood samples together with demographic, anthropometric, environmental and clinical data from the island of Hvar; to perform biochemical tests to measure glucose, insulin, uric acid and lipid levels; 2) conduct a genome-wide association analysis of metabolic traits and phenotypes using genome-wide SNP arrays (Affymetrix Genome-Wide Human SNP Array 5.0).

pht004443.v1.p1

1 ItemGroup 4 elementi

pht004444.v1.p1

1 ItemGroup 5 elementi

pht004445.v1.p1

1 ItemGroup 7 elementi

pht004446.v1.p1

1 ItemGroup 52 elementi

pht004447.v1.p1

1 ItemGroup 6 elementi

Endpoint Hospitalisation for heart failure GSK study Chronic Coronary Heart Disease NCT00799903

- 20/09/21 - 1 modulo, 3 itemgroups, 43 elementi, 1 linguaggio
Itemgroups: Investigator section, CEC Section, CEC Status
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Endpoint Hospitalisation for heart failure - Repeating form (Scheduled visits)

Lifestyle Questionnaire GSK study Chronic Coronary Heart Disease NCT00799903

- 20/09/21 - 1 modulo, 11 itemgroups, 73 elementi, 1 linguaggio
Itemgroups: Diet, Alcoholic drinks, Weekly activity, Physical activity, Health-related limitations in physical activity, Symptoms limiting physical activity, Sleep, Stress assessment, Lifestyle comparison before and after heart problem, Lifestyle since first heart problem, Socio-economic
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Lifestyle Questionnaire.

Eligibility Coronary Artery Disease NCT00287690

- 20/09/21 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00287690

EUROASPIRE III- Coronary heart disease HRI Interview Questionnaire - HRI Interview Questionnaire

- 17/09/21 - 1 modulo, 12 itemgroups, 272 elementi, 1 linguaggio
Itemgroups: Demographic Information, Smoking, Diet/Body weight, Physical activity, Blood pressure,Cholesterol and Diabetes, Risk factor awareness and targets, Lifestyle changes, Risk perception, Medication, Family history of cardiovascular disease, Physical measurements, Blood sample
Provided by Prof. Keil Source: Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID: 19286092

EUROASPIRE III- Coronary heart disease HRI Record Questionnaire - HRI Record Questionnaire

- 17/09/21 - 1 modulo, 3 itemgroups, 133 elementi, 1 linguaggio
Itemgroups: Inclusion criteria, Personal information, HRI Record Questionnaire
Provided by Prof. Keil Source: Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID: 19286092

Eligibility Coronary Artery Disease NCT00233792

- 06/10/20 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent; ODM derived from: https://clinicaltrials.gov/show/NCT00233792

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Coronary heart disease (Koronare Herzerkrankung)

- 01/10/20 - 1 modulo, 6 itemgroups, 26 elementi, 1 linguaggio
Itemgroups: Patient-ID, Diagnostic analysis: cardiac symptoms, Diagnostic analysis: severity, Ischemia diagnostic procedure, Course of treatment: Intervention, Medication during transport to hospital
A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. In this questionnaire specific items on coronary heart disease patients are collected.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial